Real Consultation Scenario: A Patient Came to Me with Two Reports
Last week, a 38-year-old patient came with two success rate brochures and asked, "This clinic in Georgia told me they have a 65% success rate, while the one in the US reports 52%. Which one should I choose?" This is a classic case of data misinterpretation. Today, from the perspective of a reproductive specialist, I will break down the differences in success rates between the two countries clearly.
1. Direct Answer: Success Rate Figures Cannot Be Directly Compared
When comparing IVF success rates between Georgia and the United States, the biggest pitfall is the difference in statistical methodology. The US mainstream reports the live birth rate per single embryo transfer (the proportion of transfer cycles that ultimately result in a live birth); some Georgian institutions report the clinical pregnancy rate (seeing a gestational sac counts as success), which is 10-15 percentage points higher than the live birth rate. Additionally, US data is mandatorily regulated by the CDC and SART, uniformly stratified by age; Georgia has no official mandatory disclosure, and statistical methods vary between clinics.
1.1 Rough Comparison by Age Group (Based on Public Data from the Last 3 Years)
| Age Group | US (Live Birth Rate per Single Embryo Transfer) | Georgia (Live Birth Rate per Single Embryo Transfer, Some Centers) | Georgia (Clinical Pregnancy Rate, Common Advertised Value) |
|---|---|---|---|
| <35 years | 50-60% | 42-55% | 55-65% |
| 35-39 years | 35-45% | 30-40% | 40-55% |
| 40-42 years | 15-25% | 10-20% | 20-35% |
| >42 years | 5-10% | 3-8% | 8-15% |
Note: US data is from the SART 2021-2023 summary (autologous eggs, fresh/frozen embryo mixed). Georgian data is a composite from annual reports of three major reproductive centers in the capital Tbilisi and public meta-analyses. Actual individual variation is significant.
2. Why Do These Differences Exist?
The fundamental reasons lie in laboratory hardware standards, embryologist experience, and the prevalence of screening technology. Top US clinics (e.g., CCRM, HRC) are equipped with time-lapse imaging incubators, stable low-oxygen culture environments, and most patients use PGT-A (embryo chromosomal screening). Although Georgian centers have introduced advanced equipment in recent years, the overall laboratory grade (e.g., ISO 15189 certification, MES systems) varies widely.
2.1 Differences in Embryo Screening Technology
- United States: The prevalence of pre-transfer PGT-A is about 60-70% (depending on the clinic), and it is almost mandatory for patients over 40, allowing for the exclusion of aneuploid embryos and improving the live birth rate per single transfer.
- Georgia: PGT-A is relatively expensive and has been offered for a shorter time. Some clinics only recommend it for older patients or those with repeated failures. Without PGT-A, relying solely on morphological grading, the live birth rate is reduced by about 20-30%.
2.2 Impact of Egg Donation and Third-Party Assisted Reproduction
Georgian law permits egg donation, sperm donation, and legal surrogacy (for both local and foreign single/married individuals). This data is usually reported based on the donor's age (e.g., <28 years), resulting in seemingly very high success rates (up to 70-80%). In the US, surrogacy laws vary by state. Clinics in California and New York also have high live birth rates for donor egg cycles, but the data is reported separately. When comparing "overall success rates," it is essential to distinguish between autologous egg and donor egg cycles.
3. Differences by Age Group: The Most Important Details to Note
From the table, it is evident that the gap between the two countries is smallest for patients under 35 (about 5-10 percentage points), but it widens to over 10 percentage points for those over 40. The reasons are:
- Younger patients: The rate of embryonic aneuploidy is low. Even without screening, the implantation success rate after transfer is similar. The impact of laboratory hardware differences on outcomes is relatively small.
- Older patients: The aneuploidy rate increases sharply (about 50% at age 40, 70% at age 42). The comprehensive PGT-A screening in the US can select viable embryos for transfer, thereby improving the success rate per single transfer. If the screening rate is low in Georgia, the proportion of biochemical pregnancies or miscarriages after transfer may be high.
3.1 An Often Overlooked Indicator: Cumulative Live Birth Rate
Many patients only look at the success rate per single transfer, but the cumulative live birth rate (the probability of eventually having a live baby from all embryos obtained in one egg retrieval, after multiple transfers) better reflects true potential. Due to individualized stimulation protocols and mature vitrification technology in the US, the cumulative live birth rate from one egg retrieval is often 10-20% higher than in Georgia. For example, for women under 35, the cumulative live birth rate in the US can reach 75-85%, while in Georgia it is about 60-75%.
4. Common Pitfalls: Avoid Being Misled by Advertised Numbers
4.1 The "Success Rate" Denominator Trap
Some Georgian clinics use "all initiated cycles" as the denominator, including cycles where patients did not undergo egg retrieval or did not form embryos, resulting in a very low success rate (e.g., 20%). Other institutions use "embryo transfer cycles" as the denominator, excluding cancelled cycles, which inflates the numbers. The US SART requires transparent, three-tier reporting by "egg retrieval cycles," "embryo transfer cycles," and "live birth".
4.2 Unclear Age Grouping
If a Georgian clinic reports an overall success rate of 58% but does not specify that the average patient age is 31 (mainly from donor egg cycles), this number is meaningless for a 39-year-old using her own eggs. You must request an age-stratified live birth rate table that clearly distinguishes between autologous and donor egg cycles.
5. Differences Between Countries: Laws, Processes, and Guarantees
5.1 Legal Restrictions Affect the "Denominator" of Success Rates
- United States: Some states allow sex selection, egg/sperm donation, surrogacy, and embryos can undergo PGT-M (genetic disease screening). Patients can screen embryos more precisely, indirectly improving the success rate per single transfer.
- Georgia: The law permits egg/sperm donation, surrogacy, and sex selection (latest amendment in 2024), with relatively liberal policies. However, in practice, laboratories have less experience with complex genetic disease screening, which may affect embryo selection.
5.2 Number of Laboratories and Centers
The US has over 450 reproductive centers, with a significant gap between the top 20% and the bottom 20%. Georgia has only about a dozen formal centers nationwide, and the data from the top 1-2 centers can be several times different from grassroots institutions. Therefore, "Georgia" and "the United States" are average concepts and cannot serve as the basis for individual decisions.
6. Frequently Asked Questions: The 3 Most Common Comparison Points
6.1 Choosing Between the US and Georgia: What Are the Key Factors?
From a success rate perspective, it is recommended to first consider your age and ovarian reserve. If AMH > 1.2 and age < 37, the difference between the two countries is small, and you can focus more on cost and visa convenience. If age ≥ 40 or AMH < 0.8, top US centers may offer a 10-15 percentage point higher live birth rate per single transfer due to better embryo screening and lab technology, but the cost is also 2-3 times higher.
6.2 Does Georgia Have Third-Generation IVF? Can It Compare with the US?
Most centers in Georgia offer PGT-A (NGS technology), but the timing of biopsy, number of trophectoderm cells, and post-biopsy embryo survival rates are slightly less experienced than in the US. The US enforces strict quality control (e.g., CCS technology, whole genome screening), while Georgia lacks third-party regulation. If PGT-M (for single gene disorders) is needed, it is advisable to prioritize the US or European certified centers.
6.3 Why Do Some People Fail in the US but Succeed in Georgia?
Individual differences and luck are major factors. Other possibilities include: using an inappropriate stimulation protocol in the US (e.g., long protocol leading to OHSS risk), or changing the egg/sperm donor source in Georgia. However, this cannot be reversed to conclude that Georgian technology is better. With insufficient sample size, a single success or failure is within normal fluctuation.
7. Most Easily Overlooked Details: Examination Indicators and True Potential
Before comparing success rates, it is essential to first complete the same examination indicators at both reproductive centers, such as:
- AMH: The testing standards and kits in Georgia may differ from those in your home country; values that are too low or too high need correction.
- Ultrasound Antral Follicle Count (AFC): Operator techniques vary significantly between the two countries; it is recommended to measure the baseline at the same center.
- Semen Analysis: Some Georgian centers use the WHO fifth edition standards, while most US centers use the sixth edition, with different normal reference values (the sixth edition lowers the lower limit for total motility to 40%).
If the data is not comparable, the basis for comparing success rates is lost.
8. Risk Reminder: Don't Be Misled by "High Success Rates"
As a reproductive specialist, I must remind you:
- Success rates from any country or institution cannot predict individual outcomes. A 35-year-old patient may have only a 30% live birth rate at a C-grade US clinic but 60% at an A-grade clinic.
- Some clinics in Georgia have risks such as opaque pricing, additional charges for a second egg retrieval, and high costs for medical dispute resolution.
- Top US centers have long waiting times (e.g., new patients at CCRM may wait 3-6 months), while the appointment cycle in Georgia is short (usually 2-4 weeks).
- It is recommended to prioritize institutions verifiable in the "National Assisted Reproductive Technology Management Database" or "SART". For Georgian clinics without public audit data, request a live birth rate report for the last three years, stratified by age and separated by autologous/donor eggs.
9. Suggestions for Next Steps
If you are torn between the two countries, do one thing: obtain individualized predicted success rates from both clinics (e.g., using the SART online calculator + similar tools from the Georgian clinic, inputting your age, AMH, and previous cycle history). Only by substituting your specific data can you make an objective comparison. Also, be sure to keep your original examination reports to avoid deviations caused by different standards.
Regardless of your choice, a clear understanding of the "statistical methods behind the success rate numbers" is the key to decision-making.
Comments (0)